Literature DB >> 31309391

Emphysematous pyelonephritis treatment strategies in correlation to the CT classification: have the current experience and prognosis changed?

Mohamed Mohamed Elawdy1, Yasser Osman2, Rasha T Abouelkheir2, Samer El-Halwagy3, Bassam Awad4, Mohsen El-Mekresh5.   

Abstract

PURPOSE: In view of the differences in early and late management experiences based on Huang and Tseng CT classification of emphysematous pyelonephritis (EP), our study included 34 patients aimed to re-correlate the current management plans with CT classification.
METHODS: A retrospective review from January 2009 to December 2018, in patients with primary or final diagnosis of EP. Data included; patients' demographics, routine laboratory and imaging work-up. CT was performed for all, and images were classified based on Huang and Tseng classification. The CT classification was correlated to the laboratory parameters and the final treatment plans. Data were collected and analyzed using SPSS®.
RESULTS: Complete data for 34 patients were analyzed. The majority (70%) had positive urine culture, and Carbapenems and Ureidopenicillin were the most commonly used antibiotics. Based on CT classification, 75% (26/34) of the patients were in class I and II, 6 cases with class IIIa, and only two with class IIIb, with no cases of class IV. All patients in class I and II responded well to the medical therapy, and eight required PCN/DJ. Four required nephrectomy in class III, with zero mortality.
CONCLUSION: Patients in class I and II comprise the majority of EP patients, and respond well to medical treatment with excellent outcome. Insertion of PCN and DJ are not required routinely, but with urinary obstruction requiring drainage, and a few cases who required nephrectomy-all with class III. Our data show improvement in the overall survival in patients for EP.

Entities:  

Keywords:  Emphysematous pyelonephritis; Huang and Tseng CT classification; Treatment

Mesh:

Year:  2019        PMID: 31309391     DOI: 10.1007/s11255-019-02220-3

Source DB:  PubMed          Journal:  Int Urol Nephrol        ISSN: 0301-1623            Impact factor:   2.370


  13 in total

1.  Emphysematous pyelonephritis: Changing trend of clinical spectrum, pathogenesis, management and outcome.

Authors:  Ashok Kumar Sokhal; Manoj Kumar; Bimalesh Purkait; Ankur Jhanwar; Kawaljit Singh; Ankur Bansal; Satyanarayan Sankhwar
Journal:  Turk J Urol       Date:  2017-01-27

2.  Emphysematous pyelonephritis: clinicoradiological classification, management, prognosis, and pathogenesis.

Authors:  J J Huang; C C Tseng
Journal:  Arch Intern Med       Date:  2000-03-27

3.  [Results of conservative management of emphysematous pyelonephritis].

Authors:  Ahmed Saadi; Haroun Ayed; Abderrazak Bouzouita; Mohamed Cherif; Walid Kerkeni; Selim Selmi; Riadh Ben Slama; Amine Derouiche; Mohamed Chebil
Journal:  Nephrol Ther       Date:  2016-10-24       Impact factor: 0.722

4.  Emphysematous pyelonephritis: a 15-year experience with 20 cases.

Authors:  A A Shokeir; M El-Azab; T Mohsen; T El-Diasty
Journal:  Urology       Date:  1997-03       Impact factor: 2.649

Review 5.  Current management of emphysematous pyelonephritis.

Authors:  Alan R Pontin; Richard D Barnes
Journal:  Nat Rev Urol       Date:  2009-05       Impact factor: 14.432

6.  Risk factors for mortality in patients with emphysematous pyelonephritis: a meta-analysis.

Authors:  Matthew E Falagas; Vangelis G Alexiou; Konstantina P Giannopoulou; Ilias I Siempos
Journal:  J Urol       Date:  2007-07-16       Impact factor: 7.450

7.  Emphysematous Pyelonephritis Case Series From South India.

Authors:  Mahesh Eswarappa; Sarita Suryadevara; Manns Manohar John; Mahesh Kumar; Sujeeth Bande Reddy; Mohammed Suhail
Journal:  Kidney Int Rep       Date:  2017-12-08

8.  Emphysematous pyelonephritis: Our experience with conservative management in 14 cases.

Authors:  Pramod Kumar Sharma; Ritu Sharma; Mukesh K Vijay; Punit Tiwari; Amit Goel; Anup K Kundu
Journal:  Urol Ann       Date:  2013-07

9.  Emphysematous pyelonephritis: A 10-year experience with 26 cases.

Authors:  Raiz Ahmad Misgar; Idrees Mubarik; Arshad Iqbal Wani; Mir Iftikhar Bashir; Mahroosa Ramzan; Bashir Ahmad Laway
Journal:  Indian J Endocrinol Metab       Date:  2016 Jul-Aug

10.  Double J stenting: A rewarding option in the management of emphysematous pyelonephritis.

Authors:  Debiprasad Das; Dilip Kumar Pal
Journal:  Urol Ann       Date:  2016 Jul-Sep
View more
  2 in total

Review 1.  Prevalence and Risk Factors of Mortality in Emphysematous Pyelonephritis Patients: A Meta-Analysis.

Authors:  Xuan Thai Ngo; Tuan Thanh Nguyen; Ryan W Dobbs; Minh Sam Thai; Duc Huy Vu; Le Quy Van Dinh; Khoa Quy; Hieu Trong Le; Tien-Dat Hoang; Hanh Thi Tuyet Ngo; Trinh Ngoc Khanh Van; Ho Yee Tiong; Huy Gia Vuong
Journal:  World J Surg       Date:  2022-07-08       Impact factor: 3.282

Review 2.  A systematic review and meta-analysis of risk factors and treatment choices in emphysematous pyelonephritis.

Authors:  Rajeev Desai; Deepak Batura
Journal:  Int Urol Nephrol       Date:  2022-02-01       Impact factor: 2.370

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.